9月24日 | 上午场公司介绍—药通中国2024秋季论坛

AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of drugs targeting major unmet medical needs. The Company is based in Paris and has been listed on Euronext since 2010 (compartment B, Paris, France). AB Science has 50 employees, mostly dedicated to R&D activities.

Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic diseases.

TaiRx, Inc. was founded in 2011 under the strategic alliance of Formosa Laboratories, Inc. and Efficient Pharma Management Corporate to develop a new generation of oncology molecule. In 2013, TaiRx started a series of financing and expanded the drug pipeline. In addition to cancer treatment, we also extended our reach to the therapy of other major diseases. TaiRx has a rich product pipeline and many of our products are moving rapidly into various clinical stages to ensure the safety and efficacy of the drug products. TaiRx continues to search for novel cures for serious diseases and deliver them to the medical community to help those in need.

As a biotech company focused on cancer drug discovery and development, our AI technology allows us to identify promising new treatments and bring them closer to clinical use. By addressing unmet needs in cancer care, we aim to create effective new drugs, reduce the risk of failure in development, and ensure these treatments reach patients with fewer side effects and greater effectiveness.

With more than 20 years of research in cancer, our scientific team provides the knowledge and expertise to develop a robust and expanding pipeline of novel cancer therapeutics, featuring first-in-class agents. Our most advanced project is an ADC for pancreatic cancer with no competition targeting the same pathway. The proof of concept (PoC) has been completed, demonstrating that after 21 days of treatment, tumors in the control group tripled in size, while those treated with the ADC experienced complete remission. Additionally, we are developing a TEAD inhibitor, a PARP inhibitor, a PROTAC for breast cancer, and another potential ADC.

Pleco Therapeutics BV is a private Dutch biopharmaceutical company developing a portfolio of therapies in the field of cancer medicine. They use a novel approach that aims to increase the sensitivity of cancer cells to chemotherapy. They are transforming care for difficult-to-treat cancers by adopting this innovative approach to overcome drug resistance.

Pleco works with a global network of academic and clinical centers, and contract research organizations to develop and test novel products that increase the effectiveness of chemotherapy, thus changing the balance of outcomes for cancer patients, improving treatment-outcome and extending life. Their experienced team has a fast-to-market development strategy. The company has clinical proof of concept and has been granted the Orphan Drug Designation by the FDA.

Nascent Biotech is a Florida-based company focused on the development and delivery of human antibodies and cytokine responses for the treatment of cancer. The innate ability of the intelligence of the natural human immune system to generate a cancer specific response combined with Nascent Biotech’s technical skills opens the door for immunologically based therapeutics for human cancer. Nascent Biotech is using and developing human antibodies and cytokine responses obtained from the innate natural human immune response as a drug discovery platform for identifying new antibodies and antigens for commercialization.

Immunwork, Inc. is a biotechnology company that specializes in developing innovative drugs using its proprietary “Multi-Arm Linker” platforms. The company’s platforms are designed to conjugate various drug moieties together and create new drugs, including antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), and ultralong-acting peptides. These novel drugs address severe clinical conditions such as cancer, diabetes, obesity, and cardiovascular diseases, among others. The concept of “T-E pharmaceuticals,” which guides the company’s drug development efforts, involves creating drug molecules that contain both targeting (T) and effector (E) moieties. This approach ensures that the drugs are precisely delivered to specific tissues or cells, enhancing efficacy and minimizing toxicity.

Immunwork is committed to advancing its drug candidates into clinical applications to help patients in need. With the rise of personalized and precision medicine, Immunwork’s modular design feature, enabled by the T-E pharmaceuticals concept, is especially well-suited for developing a new generation of therapeutics. By leveraging its Multi-Arm Linker platform, Immunwork aims to create additional novel drug candidates that can address unmet medical needs in a variety of therapeutic areas.

EpiEndo is a clinical-stage biopharmaceutical company developing an oral drug for chronic obstructive pulmonary diseases (COPD), focusing on enhancing the epithelial immune response to reduce the frequency, duration and severity of exacerbations.

NGB Innovations is a human factors-oriented technology company specializing in hardware design and product manufacturing. Founded in 2023, the company is dedicated to creating innovative solutions that improve biotechnology practices across medical, agricultural, and space industries. NGB Innovations’ products are known for their meticulous attention to detail, precision, novelty, and quality. The company was honored as a finalist for the AUS SPACE 24 Start-up of the Year and was selected to present at the ARCS Start-up Session in Sydney in 2024.

The company’s first MVP stage product line, NG-C, is a cutting-edge device that combines cell lysing and gene cutting into one process, significantly reducing the overall working time from hours to just 5-10 minutes. NG-C is unique in that it operates without harsh chemicals, enzymes, or detergents, which have traditionally posed challenges in biotechnology. This innovation not only minimizes these issues but also provides a new method for extracting genes and proteins with food-grade safety on a large scale. NG-C’s development involved extensive testing, with over 100 tests conducted at the proof-of-concept stage and more than 20 tests completed on the MVP product, all demonstrating stable performance. NGB Innovations plans to initiate its first novel biomarker finding test once funding is secured.